Angiotensin II Induces Monocyte Chemoattractant Protein-1 Gene Expression in Rat Vascular Smooth Muscle Cells

From the Division of Cardiology, Department of Medicine, Emory University School of Medicine (X.C., P.E.T., M.T.O., R.W.A., R.M.M.), Atlanta, Ga, and AtheroGenics, Inc (R.M.M.), Norcross, Ga.

Correspondence to Russell M. Medford, MD, PhD, AtheroGenics, Inc, 3065 Northwoods Circle, Norcross, GA 30071. E-mail rmedford{at}atherogen.com

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Monocyte infiltration into the vessel wall, a key initial step in the process of atherosclerosis, is mediated in part by monocyte chemoattractant protein-1 (MCP-1). Hypertension, particularly in the presence of an activated renin-angiotensin system, is a major risk factor for the development of atherosclerosis. To investigate a potential molecular basis for a link between hypertension and atherosclerosis, we studied the effects of angiotensin II (Ang II) on MCP-1 gene expression in rat aortic smooth muscle cells. Rat smooth muscle cells treated with Ang II exhibited a dose-dependent increase in MCP-1 mRNA accumulation that was prevented by the AT₁ receptor antagonist losartan. Ang II also activated MCP-1 gene transcription. Inhibition of NADH/NADPH oxidase, which generates superoxide and H₂O₂, with diphenylene iodonium or apocynin decreased Ang II–induced MCP-1 mRNA accumulation. Induction of MCP-1 gene expression by Ang II was inhibited by catalase, suggesting a second messenger role for H₂O₂. The tyrosine kinase inhibitor genistein and the mitogen-activated protein kinase kinase inhibitor PD098059 inhibited Ang II–induced MCP-1 gene expression, consistent with a mitogen-activated protein kinase-dependent signaling mechanism. Ang II may thus promote atherogenesis by direct activation of MCP-1 gene expression in vascular smooth muscle cells.

Key Words: angiotensin II • monocyte chemoattractant protein-1 • vascular smooth muscle cell • AT₁ receptor

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The earliest recognizable lesion of atherosclerosis is the "fatty streak," which partly consists of an aggregate of lipid-laden macrophages (foam cells) within the intimal wall.¹ Monocyte infiltration into the vessel wall is a key initial step in the formation of the atherosclerotic lesion.^{1 2} The recruitment of these macrophages to the lesion is mediated initially by an increased gradient of chemotactic activity and is followed by monocyte adherence to the endothelium and migration into the neointima. Monocyte chemoattractant protein-1 (MCP-1) is chemotactic for monocytes both in vitro and in vivo.^{3 4} MCP-1 has been detected in atherosclerotic lesions from both human and experimental animals but not in normal arteries, suggesting that it may play a significant role in the pathogenesis of atherosclerosis.^{5 6}

Hypertension is an established risk factor for the development of atherosclerosis, but the underlying molecular and cellular mechanisms are unclear.^{7 8} Several lines of experimental and clinical evidence suggest a potential role of the renin-angiotensin system in contributing to the pathogenesis of atherosclerosis. Epidemiological studies suggest that hypertensive patients with an activated renin-angiotensin system have a higher incidence of myocardial infarction than other forms of hypertension.^{9 10 11 12} Treatment of patients with left ventricular dysfunction with angiotensin-converting enzyme (ACE) inhibitors reduces the incidence of recurrent myocardial infarction and mortality.^{13 14} ACE inhibitors reduce atherosclerotic lesions in several animal models, including Watanabe hyperlipidemic rabbits,^{15 16} cholesterol-fed minipigs,¹⁷ monkeys,¹⁸ and mice.¹⁹

Angiotensin II (Ang II), an important component of the renin-angiotensin system and a vasoactive peptide, exerts numerous effects on the cardiovascular system. In addition to its vasoconstrictor role, Ang II directly induces oxidative stress in the vasculature. It generates superoxide anions by activating membrane-bound NADH/NADPH oxidase in cultured rat aortic smooth muscle cells (RASMCs) and in aortas of rats made hypertensive by Ang II infusion.^{20 21} Cytokine-induced MCP-1 gene expression is regulated through an oxidation-reduction (redox)-sensitive mechanism.^{22 23} In this study, we tested the hypothesis that Ang II may contribute to atherosclerosis through induction of oxidative stress and redox-sensitive inflammatory gene expression in the vasculature. Our results demonstrate the following: (1) Ang II stimulates MCP-1 gene expression in cultured RASMCs through an AT₁ receptor-mediated mechanism; (2) this induction is dependent on redox-sensitive signaling events involving activation of NADH/NADPH oxidase and generation of H₂O₂; and (3) this induction is dependent on protein tyrosine phosphorylation and activation of a mitogen-activated protein kinase (MAP kinase) cascade.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
Ang II, genistein, N-acetyl cysteine (NAC), and H₂O₂ were obtained from Sigma Chemical Co. Ang II was also obtained from Calbiochem. Losartan was kindly provided by Ronald D. Smith, PhD (Du Pont Pharmaceutical Co). PD123319 and PD098059 were obtained from Research Biochemicals International. Diphenylene iodonium (DPI) was obtained from Toronto Research Chemicals, Inc. Diethylamine-nitric oxide (DETA-NO) was obtained from Alexis Biochemicals Corp. Pyrrolidine dithiocarbamate (PDTC) was obtained from Fluka Biochemical Corp. Catalase was obtained from Boehringer Mannheim Corp. Pervanadate was prepared as previously described.²⁴ All batches of Ang II were tested, and found negative, for the presence of endotoxin using a Limulus amebocyte lysate assay kit (ICN Pharmaceuticals).

Cell Culture
RASMCs were generously provided by Dr K.K. Griendling as well as Dr P. Delafontaine (Division of Cardiology, Emory University School of Medicine). RASMCs were isolated from male Sprague-Dawley rat thoracic aortas by enzyme digestion and were characterized to be vascular smooth muscle cells as previously described.²⁵ RASMCs were grown in DMEM (Gibco Chemical Co) supplemented with 10% FBS, L-glutamine, penicillin (100 U/mL), and streptomycin (100 µg/mL). All experiments were conducted on cells at passages 5 to 15. RASMCs were serum-starved for 24 hours by incubating 95% confluent cells in DMEM with 0.1% FBS. Cell cultures were incubated at 37°C in a humidified atmosphere of 5% CO₂-95% air.

Preparation of RNA and Northern Blot Analysis
Total cellular RNA was isolated by a single extraction using TriPure reagent (Boehringer Mannheim), and 15 µg were size fractionated using 1% agarose-formaldehyde gels in the presence of 1 µg/mL ethidium bromide. The RNA was transferred to a nitrocellulose filter and covalently linked by UV irradiation using a Stratalinker UV cross-linker. Hybridizations were performed at 68°C for 1 hour in QuickHyb solution (StrataGene) for rat MCP-1 cDNA. Approximately 1 to 2x10⁶/mL of ³²P-labeled probes were used for hybridization. After hybridization, filters were washed with a final stringency of 0.2x SSC at 60°C for 30 minutes. The cDNAs used were a 700-bp EcoRI fragment of rat MCP-1 cDNA (generously provide by Dr Toshi, National Cancer Institute) and the 1.2-kb PstI fragment of rat GAPDH cDNA. Autoradiography was performed with an intensifying screen at -70°C or with a PhosphorImager 445sI (Molecular Dynamics). Laser densitometry and digital analysis of scanned images were used for quantification of autoradiographs.

ELISA for MCP-1
Rat MCP-1 concentration was determined by ELISA, with recombinant rat MCP-1 used as a standard as previously described.²⁶ Briefly, flat-bottomed 96-well ELISA plates (CorningCostar) were coated with 100 µL/well of goat anti–MCP-1 antibody (Santa Cruz Biotechnology Inc, 1 µg/mL in 0.6 mol/L NaCl, 0.26 mol/L H₃BO₃, and 0.08 N NaOH [pH 9.6]) for 16 hours at 4°C and then washed with PBS and 0.05% Tween (wash buffer). This buffer was used to wash the plates throughout the assay. Nonspecific binding sites were blocked with incubation in 2% BSA in PBS for 90 minutes at 37°C. The plates were washed 3 times. Then, cultured medium (neat and 10-fold concentrated, 100 µL) from each sample was added and incubated for 1 hour at 37°C. A serial dilution of recombinant rat MCP-1 (PeproTech Inc, 10 to 120 ng/mL) was used to obtain a standard curve. The plates were washed and rabbit anti-rat MCP-1 antibody (PeproTech Inc, 0.5 µg/mL) was added and incubated for 30 minutes at 37°C. This was followed by secondary binding with a horseradish peroxidase-conjugated goat anti-rabbit IgG antibody. Quantification was performed by determination of colorimetric conversion at 450 nm of 3,3',5,5'-tetramethylbenzidine. The standard concentration curve for MCP-1 measured by this method was linear from 10 to 120 ng/mL. Using this technique, MCP-1 protein could only be detected in 10-fold concentrated medium from Ang II–treated cells. Thus, 10-fold concentrated medium was used to determine MCP-1 levels in all experiments. Conditioned medium was concentrated using Centriprep-10 Concentrators (Amicon).

Nuclear Run-on Transcription Assays
RASMCs were treated with or without Ang II (100 nmol/L) for 1 hour, and nuclei were isolated. Nuclear run-on assays were performed with 3x10⁷ cells/treatment as previously described.²⁷ For each assay, nuclei were resuspended in 300 µL of transcription buffer containing 100 µCi of [-³²P]UTP and incubated for 30 minutes at 30°C. The labeled RNA was purified by single extraction using TriPure and hybridized to a nylon membrane filter that contained alkali-denatured target cDNA. The filters were prepared by slot blotting of 5 µg of target cDNA and covalently linked by UV irradiation using a Stratalinker UV cross-linker. The cDNAs used were the 700-bp EcoRI fragment of rat MCP-1 cDNA and the 1.2-kb PstI fragment of rat GAPDH cDNA.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Ang II Induces MCP-1 mRNA Accumulation and Secretion of MCP-1 in Cultured RASMCs
To investigate whether Ang II can directly increase MCP-1 mRNA accumulation, serum-starved RASMCs were treated with or without Ang II for 6 hours. By Northern analysis, there was little MCP-1 mRNA expression in unstimulated RASMCs (Figure 1A, lane 1). Ang II induced a dose-dependent increase in MCP-1 mRNA accumulation. There was a 3.4-fold increase in MCP-1 mRNA accumulation with 1 nmol/L Ang II (lane 2), and maximal induction by Ang II occurred at a concentration of 10 nmol/L (lane 3). The increase in MCP-1 mRNA levels could be detected after 1 hour of Ang II stimulation, peaking at 4 hours and returning to baseline at 24 hours after Ang II treatment (Figure 1B). To examine whether the increase in MCP-1 mRNA levels in response to Ang II is associated with an increase in MCP-1 production, MCP-1 protein levels in the media were determined by ELISA. Extracellular MCP-1 protein concentration increased markedly from 0.03 ng/mL to 3.2 ng/mL and 4.4 ng/mL after 12 hours and 24 hours of Ang II stimulation in RASMCs, respectively (Figure 1C).

View larger version (27K): [in this window] [in a new window]   Figure 1. Effects of Ang II on MCP-1 expression in cultured RASMCs. A, RASMCs were treated with Ang II (1 to 100 nmol/L; lanes 2 to 4) for 6 hours. Total RNA was isolated, size-fractionated by electrophoresis, transferred to a nitrocellulose membrane, hybridized with 32P-labeled rat MCP-1–specific cDNA, and visualized by autoradiography. Two independent experiments showed similar results. B, Total RNA was isolated from untreated or Ang II–treated (100 nmol/L) RASMCs at indicated times. MCP-1 mRNA levels were determined by Northern analysis as described in panel A. Two independent experiments showed similar results. C, Conditioned medium was collected at 12 and 24 hours after Ang II (100 nmol/L) treatment. MCP-1 levels were determined by ELISA as described in Materials and Methods. Values represent mean±SEM (n=4). *P<0.05 vs control group (CTL).

Ang II–Induced MCP-1 mRNA Expression in RASMCs Is Blocked by AT₁ Receptor Blockade
To determine whether Ang II–induced MCP-1 gene expression is mediated by the AT₁ receptor, RASMCs were pretreated with the AT₁ receptor antagonist losartan. One hundred-fold molar excess of losartan prevented the increase in MCP-1 mRNA accumulation caused by Ang II (100 nmol/L; Figure 2, lane 4). Losartan had no effect on tumor necrosis factor- (TNF-)-induced MCP-1 mRNA expression (lane 5). Pretreatment of RASMCs with 100-fold molar excess of the AT₂ receptor antagonist PD123319 had no effect on Ang II–induced MCP-1 mRNA expression (data not shown). These data suggest that the induction of MCP-1 gene expression by Ang II is mediated through AT₁ receptors in RASMCs.

View larger version (40K): [in this window] [in a new window]   Figure 2. The AT1 receptor antagonist losartan inhibits Ang II–induced MCP-1 mRNA accumulation in RASMCs. RASMCs were pretreated with or without losartan (10 µmol/L) for 15 minutes and then exposed to Ang II (100 nmol/L) or TNF- (100 U/mL) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Three independent experiments showed similar results.

Ang II Induces MCP-1 Gene Transcription in RASMCs
To investigate whether Ang II can induce MCP-1 gene transcription, nuclear run-on experiments were performed. RASMCs were treated with Ang II (100 nmol/L) for 1 hour, nuclei were isolated, and radiolabeled RNA generated by these nuclear preparations was hybridized to rat MCP-1 cDNA or rat GAPDH cDNA. There was low basal hybridization in nontreated RASMCs (Figure 3). When RASMCs were treated with Ang II, there was a 2-fold increase in MCP-1 gene transcription. These data suggest that Ang II induces MCP-1 gene transcription in RASMCs.

View larger version (16K): [in this window] [in a new window]   Figure 3. Ang II activates MCP-1 gene transcription in RASMCs. A, RASMCs were treated with or without Ang II (100 nmol/L) for 1 hour. Nuclei were isolated, and 32P-labeled transcripts were purified. The RNA was hybridized to specific cDNA inserts of rat MCP-1 and GAPDH immobilized on a nylon filter. B, Graphic representation of MCP-1 gene transcription rates after normalization with GAPDH. Filters were imaged using the PhosphorImager 445Si (Molecular Dynamics). Values represent mean±SEM (n=3). *P<0.05 vs control group (CTL).

Ang II–Induced MCP-1 Gene Expression in RASMCs Is Abolished by Inhibitors of Membrane-Bound NADH/NADPH Oxidase
Previous studies showed that Ang II activates membrane-bound NADH/NADPH oxidase and generates superoxide anions in RASMCs.²¹ To determine whether this activation plays a role in MCP-1 gene expression, we pretreated cultured RASMCs with 2 inhibitors of flavin-binding proteins, DPI (40 µmol/L) and apocynin (200 µg/mL), for 1 hour, followed by Ang II (100 nmol/L) for 6 hours. As determined by Northern analysis, both DPI and apocynin inhibited MCP-1 mRNA accumulation in RASMCs stimulated with Ang II (Figure 4). These data suggest that NADH/NADPH oxidase is involved in Ang II–induced MCP-1 gene expression.

View larger version (39K): [in this window] [in a new window]   Figure 4. Ang II–induced MCP-1 gene expression is abolished by pretreatment with inhibitors of flavin-binding proteins. RASMCs were pretreated with DPI (40 µmol/L; lanes 3 and 4) and apocynin (200 µg/mL; lanes 5 and 6) for 1 hour and treated with Ang II (100 nmol/L; lanes 2, 4, and 6) for 6 hours. MCP-1 mRNA accumulation was determined by Northern analysis. Three independent experiments showed similar results.

H₂O₂ as a Mediator in Ang II–Induced MCP-1 Gene Expression in RASMCs
Because superoxide generated by NADH/NADPH oxidase can be converted spontaneously or enzymatically to H₂O₂, we tested whether H₂O₂ plays a direct role in Ang II–induced MCP-1 gene expression in RASMCs. RASMCs were exposed to H₂O₂ (25 to 100 µmol/L) for 3 hours. H₂O₂ induced a dose-dependent increase in MCP-1 mRNA accumulation in RASMCs after 3 hours of incubation (Figure 5A). To examine whether endogenously generated H₂O₂ is involved in the signaling pathway for Ang II–induced MCP-1 gene expression, we pretreated RASMCs with or without catalase (3000 U/mL) for 24 hours and then treated the cells with Ang II (100 nmol/L). Prolonged pretreatment of RASMCs with catalase significantly decreases platelet-derived growth factor (PDGF)-stimulated H₂O₂ generation.²⁸ Ang II–induced MCP-1 mRNA accumulation (Figure 5B, lane 2) was inhibited by catalase pretreatment (lane 4), suggesting that H₂O₂ may be involved as a second messenger in Ang II–induced MCP-1 gene expression.

View larger version (40K): [in this window] [in a new window]   Figure 5. A, H2O2 induces MCP-1 mRNA accumulation in RASMCs. RASMCs were treated with H2O2 (25 to 100 µmol/L) for 2 hours. MCP-1 mRNA levels were determined by Northern analysis. B, Catalase inhibits Ang II–induced MCP-1 mRNA accumulation in RASMCs. RASMCs were pretreated with catalase for 24 hours (3000 U/mL; lanes 3 and 4) and then exposed to Ang II (100 nmol/L; lanes 2 and 4) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Three independent experiments showed similar results.

Nitric Oxide Inhibits Ang II–Induced MCP-1 mRNA Accumulation in RASMCs
In endothelial cells, exogenous nitric oxide (NO) inhibits cytokine-induced expression of redox-sensitive genes such as vascular cell adhesion molecule-1 and MCP-1.^{29 30} To examine whether NO can similarly inhibit Ang II–induced MCP-1 mRNA accumulation, RASMCs were pretreated with or without the NO donor, DETA-NO (100 µmol/L), for 1 hour. Pretreatment with DETA-NO decreased Ang II–induced MCP-1 mRNA accumulation (Figure 6, lane 4). DETA alone had no effects on basal or Ang II–induced MCP-1 mRNA expression (data not shown).

View larger version (40K): [in this window] [in a new window]   Figure 6. DETA-NO inhibits Ang II–induced MCP-1 mRNA accumulation in RASMCs. RASMCs were pretreated with DETA-NO for 1 hour (100 nmol/L; lanes 3 and 4) and then exposed to Ang II (100 nmol/L; lanes 2 and 4) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Three independent experiments showed similar results.

Thiol Antioxidants Did Not Block Ang II–Induced MCP-1 mRNA Accumulation in RASMCs
To examine whether thiol antioxidants can inhibit Ang II–induced MCP-1 gene expression, RASMCs were pretreated with the thiol antioxidants PDTC (100 µmol/L) or NAC (5 mmol/L) for 1 hour. Both of these antioxidants inhibit TNF--induced MCP-1 gene expression in cultured endothelial cells.²² However, neither PDTC nor NAC inhibited Ang II–induced MCP-1 mRNA accumulation in RASMCs (Figure 7A and 7B). Furthermore, NAC by itself strongly induced MCP-1 mRNA (Figure 7B).

View larger version (32K): [in this window] [in a new window]   Figure 7. Thiol antioxidants do not inhibit Ang II–induced MCP-1 mRNA accumulation in RASMCs. A, RASMCs were pretreated for 1 hour with PDTC (200 µmol/L; lanes 3 and 4) and then exposed to Ang II (100 nmol/L; lanes 2 and 4) for 6 hours. B, RASMCs were pretreated with NAC for 1 hour (5 mmol/L; lanes 3 and 4) and then exposed to Ang II (100 nmol/L; lanes 2 and 4) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Two independent experiments showed similar results.

Ang II–Induced MCP-1 Gene Expression Requires Both Tyrosine Kinase and MAP Kinase Activities
Ang II induces protein tyrosine phosphorylation in vascular smooth muscle cells.^{31 32} This signaling event mediates Ang II–induced increases in plasminogen activator inhibitor (PAI)-1 and PAI-2 mRNA expression in RASMCs.³³ However, it is unclear whether a similar signaling pathway mediates Ang II–induced MCP-1 gene expression. To determine whether an increase in tyrosine phosphorylation induces MCP-1 mRNA accumulation, RASMCs were exposed to the protein tyrosine phosphatase inhibitor pervanadate (25 to 200 µmol/L) for 3 hours. Pervanadate induced an increase in MCP-1 mRNA accumulation in RASMCs at 25 µmol/L with maximal effects at 100 µmol/L (Figure 8A). This suggests that increased protein tyrosine phosphorylation can induce MCP-1 mRNA accumulation. To determine the involvement of protein tyrosine kinase in Ang II–induced MCP-1 expression, RASMCs were pretreated with or without the specific tyrosine kinase inhibitor genistein (30 µmol/L) for 30 minutes and throughout the experiment. Genistein alone had no effect on basal MCP-1 mRNA levels (Figure 8B, lane 3). Ang II–induced MCP-1 mRNA accumulation was completely inhibited by genistein (Figure 8B, lane 4).

View larger version (34K): [in this window] [in a new window]   Figure 8. A, The protein tyrosine phosphatase inhibitor pervanadate induces MCP-1 mRNA accumulation in RASMCs. RASMCs were treated with pervanadate (50 to 200 nmol/L) for 2 hours. MCP-1 mRNA levels were determined by Northern analysis. B, Tyrosine kinase inhibitor genistein blocks Ang II–induced MCP-1 mRNA accumulation in RASMCs. RASMCs were pretreated with genistein for 1 hour (30 µmol/L; lanes 3 and 4) and then exposed to Ang II (100 nmol/L; lanes 2 and 4) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Three independent experiments showed similar results.

MAP kinases are important mediators of growth factor signal transduction.³⁴ Ang II is a strong activator of MAP kinase in RASMCs.^{35 36} To investigate whether activation of MAP kinase is involved in Ang II–induced MCP-1 mRNA expression, RASMCs were pretreated with the MAP kinase kinase inhibitor PD098059 (5 to 30 µmol/L) for 30 minutes.³⁷ PD098059 alone had no effect on MCP-1 mRNA expression (Figure 9, lane 3). Pretreatment with PD098059 inhibited Ang II–induced MCP-1 mRNA expression in a dose-dependent manner. This suggests that activation of a MAP kinase may play an important role in Ang II–induced MCP-1 expression in RASMCs.

View larger version (36K): [in this window] [in a new window]   Figure 9. The MAP kinase kinase inhibitor PD098059 blocks Ang II–induced MCP-1 mRNA accumulation in RASMCs. RASMCs were untreated (lanes 1 and 2) or pretreated with PD098059 for 1 hour (5 to 30 µmol/L; lanes 3 to 6) and then exposed to Ang II (100 nmol/L; lanes 2, 4, 5, 6) for 6 hours. MCP-1 mRNA levels were determined by Northern analysis. Three independent experiments showed similar results.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In the present study, we have demonstrated that Ang II is a potent stimulator of MCP-1 expression in cultured vascular smooth muscle cells. Ang II induced MCP-1 mRNA accumulation rapidly and with significant magnitude. Dose-response studies demonstrated a significant induction of MCP-1 mRNA levels at a physiological concentration of Ang II (1 nmol/L). Its maximal effect concentration at 10 nmol/L is similar to, or lower than, other Ang II actions that have been reported.^{33 38 39} We have also shown that Ang II–induced MCP-1 gene expression occurs through an AT₁ receptor-mediated mechanism and at least partially through increased transcriptional activity, as demonstrated by our nuclear run-on experiments.

The regulation of MCP-1 gene expression by cytokines occurs through redox-sensitive transcriptional mechanisms.^{40 41} Similarly to cytokines, Ang II–mediated MCP-1 gene expression may also be coupled to the activation of redox-sensitive transcription factors. Ang II induces oxidative stress by stimulating superoxide anion generation through membrane-bound NADH/NADPH oxidase in cultured RASMCs and in aortas of rats made hypertensive with Ang II.^{20 21} In this study, DPI and apocynin, 2 inhibitors of NADH/NADPH oxidase, suppressed Ang II–induced MCP-1 mRNA accumulation in RASMCs. Flavin-binding protein inhibitors such as DPI block Ang II–induced generation of superoxide.²¹ These data suggest that reactive oxygen species generated by flavin-binding proteins such as NADH/NADPH oxidase may be involved in the signaling cascade for Ang II–induced MCP-1 gene expression in RASMCs.

Superoxide anion can be converted spontaneously or enzymatically into H₂O₂. Both Ang II and H₂O₂ induce expression of c-fos and c-jun, nuclear activator protein-1 (AP-1) binding activity,^{42 43 44} and nuclear factor B (NF-B) binding activity.^{45 46} In this study, we demonstrated that H₂O₂ induces MCP-1 gene expression similarly to Ang II in RASMCs. Furthermore, pretreatment of RASMCs with catalase, under conditions that inhibit intracellular H₂O₂ generation,²⁸ suppressed Ang II–induced MCP-1 mRNA accumulation. These results suggest that H₂O₂ may play an important role as a second messenger in upregulating MCP-1 gene expression.

In endothelial cells, cytokines induce the expression of inflammatory genes such as MCP-1 and vascular cell adhesion molecule-1 through oxidative signals involving reactive oxygen species.^{29 30} Exogenously administered NO inhibits this induction, probably through antioxidant effects and inhibition of NF-B activation.^{29 47} The present study demonstrated that Ang II–induced MCP-1 gene expression is inhibited by an NO donor (DETA-NO) in RASMCs. These findings suggest that a relatively large production of NO can attenuate redox-sensitive inflammatory gene expression in RASMCs. NO is a free radical with both antioxidant and prooxidant properties depending on its relative concentration to other reactive species, such as superoxide anion. NO inhibits cellular superoxide-mediated lipoprotein oxidation.⁴⁸ It is possible that NO inhibits MCP-1 gene activation by decreasing H₂O₂ via interaction with superoxide to generate peroxynitrite. Alternatively, NO may suppress MCP-1 gene activation by inhibition of NF-B activation.^{29 47}

Whereas thiol antioxidants inhibit MCP-1 gene expression in response to a variety of proinflammatory stimuli in endothelial cells,⁴⁹ an important finding in this study is their inability to inhibit the induction of MCP-1 gene expression by Ang II in RASMCs. These varying sensitivities to antioxidants may reflect differences in cell type, whereby RASMCs may have unique intracellular pathways of thiol antioxidant metabolism. Consistent with this possibility, we have also observed that PDTC and NAC do not inhibit TNF--induced MCP-1 gene expression in RASMCs (unpublished observation).

Recent data demonstrated that H₂O₂ mediates PDGF-induced protein tyrosine phosphorylation and activation of MAP kinase in vascular smooth muscle cells.²⁸ Ang II increases protein tyrosine phosphorylation^{31 32} and tyrosine kinase-dependent PAI-2 gene expression in vascular smooth muscle cells.³³ Protein tyrosine kinase is also involved in activation of AP-1 DNA binding activity in myogenic cells by Ang II⁴² and in activation of NF-B by cytokines.^{50 51} The present study suggests a potential signaling role of protein phosphorylation via tyrosine kinase in Ang II–mediated MCP-1 gene expression.

MAP kinases encoded by the extracellular signal-regulated kinase (ERK) genes are a family of serine/threonine protein kinases activated as early responses to a variety of stimuli involved in cellular growth, transformation, and differentiation.³⁴ They are also involved in activation of AP-1 and NF-B.^{52 53} Two isoforms of ERK, referred to as p44^mapk (ERK1) and p42^mapk (ERK2), are activated by phosphorylation of threonine and tyrosine residues by MAP kinase kinase, also called MEK.^{54 55} Ang II rapidly activates MAP kinases, particularly ERK1 and ERK2, in vascular smooth muscle cells.^{56 57} Using a specific inhibitor of MEK activation, we demonstrated that Ang II–induced MCP-1 mRNA occurs through a PD098059-sensitive MEK. H₂O₂ appears to be an upstream signal in PDGF-induced protein tyrosine phosphorylation and activation of MAP kinase in vascular smooth muscle cells.²⁸ Consistent with our data, it is possible that H₂O₂ may activate protein tyrosine kinase and MAP kinase and mediate Ang II–induced MCP-1 gene expression.

A variety of experimental and clinical studies suggest the importance of the renin-angiotensin system in atherogenesis. Hypertensive patients with high renin profiles, who are likely to be associated with increased Ang II levels, have a higher risk for myocardial infarction than those with low renin profiles.^{9 11} Patients with the DD ACE genotype have significantly higher levels of ACE activity and increased incidence of myocardial infarction than those without this genotype.¹² Several recent clinical studies independently demonstrated significant reductions in mortality and morbidity, including decreased recurrent ischemic events, in patients treated with ACE inhibitors after suffering a myocardial infarction.^{13 14 58} Capers et al⁵⁹ have demonstrated a marked inflammatory response, characterized by the infiltration of monocytes/macrophages in the arterial walls of rats made hypertensive by infusion of Ang II. Monocyte/macrophage infiltration also occurs in the arterial walls of spontaneously hypertensive rats^{60 61} but is abolished with treatment with ACE inhibitors.⁶¹ These results and the data from the present study suggest that the proatherogenic properties of the renin-angiotensin system may occur, in part, through Ang II–mediated induction of vascular inflammatory genes such as MCP-1.

Taubman et al³⁹ and Poon et al⁶² reported that Ang II has no effects on JE/MCP-1 mRNA accumulation or monocyte chemotactic activity in cultured RASMCs. The discrepancy in these results compared with those of our study may lie in the phenotypic heterogeneity of RASMC preparations. For example, Taubman et al³⁹ and Poon et al⁶² reported that thrombin does not stimulate MCP-1 gene expression or monocyte chemoattractant activity in RASMCs, whereas Wenzel et al⁶³ reported that thrombin is a strong stimulator of MCP-1 expression and monocyte chemoattractant activity in RASMCs. We have addressed this issue of phenotypic heterogeneity by examining 2 independently derived RASMC preparations. Ang II increased MCP-1 mRNA levels in both RASMC preparations. Differences in cell isolation and preparation, culture conditions, and other factors may all have contributed to the discrepancy in the results between this study and that of Taubman et al.³⁹ In the study of Taubman et al,³⁹ Ang II treatment increased MCP-1 mRNA half life but decreased MCP-1 gene transcription. The net effect was no change in MCP-1 mRNA levels in Ang II–treated cells. We have similarly observed that Ang II increased MCP-1 mRNA stability (data not shown), but we demonstrated that Ang II can activate MCP-1 gene transcription. We and others have further demonstrated previously that when rats are made hypertensive by infusion with Ang II, there is marked increase in MCP-1 mRNA levels in rat aortas.^{59 64} Given that 95% of the cell population in the aorta consists of vascular smooth muscle cells, these data support our tissue culture studies and suggest that Ang II can stimulate MCP-1 gene expression in vascular smooth muscle cells.

In summary, our findings demonstrate that Ang II, a potent vasoconstrictor and growth factor, directly stimulates MCP-1 gene expression in the vasculature via the AT₁ receptor. This activation occurs through a redox-sensitive mechanism that appears to involve the activation of membrane-bound NADH/NADPH oxidase through generation of H₂O₂ as a second messenger. The activation of protein tyrosine kinases and that of MAP kinases also appear to be important signaling events that mediate Ang II–induced MCP-1 gene expression in RASMCs. These proinflammatory effects of Ang II may contribute to atherogenesis by promoting migration of monocytes into the vessel wall. Finally, these results may begin to provide a molecular link between hypertension, a principal risk factor for coronary artery disease, and the development of atherosclerosis.

	Acknowledgments

 
This study was supported by National Institutes of Health research grant PO1-HL-48667 (Drs Alexander and Medford) and by an unrestricted research grant from AtheroGenics, Inc (Dr Medford). This work was performed while Dr Medford was an Established Investigator of the American Heart Association.

	Footnotes

 
¹ Both authors contributed equally to this study.

Received December 1, 1997; accepted August 12, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

2. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181–190.[Abstract]

3. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkeater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;2039–2047.

4. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol. 1995;155:3610–3618.[Abstract]

5. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534–539.[Medline] [Order article via Infotrieve]

6. Nelken N, Coughlin SR, Gorden D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127.

7. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155–161.[Abstract/Free Full Text]

8. Doyle AE. Hypertension and vascular disease. J Cardiovasc Pharmacol. 1992;19:S7–S10.

9. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098–1104.[Abstract]

10. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616–619.[Abstract/Free Full Text]

11. Alderman MH. Plasma renin activity and coronary heart disease: are they related? Curr Opin Nephrol Hypertens. 1995;4:201–203.[Medline] [Order article via Infotrieve]

12. Cambien F, Poirer O, Lecerf L, Evens A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Richard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644.[Medline] [Order article via Infotrieve]

13. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem S, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;:240:1173–1178.

14. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J. 1994;128:1328–1332.[Medline] [Order article via Infotrieve]

15. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;12:327–331.[Free Full Text]

16. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20:473–477.[Abstract/Free Full Text]

17. Andersson RG, Jacobsson L, Persson K. Angiotensin converting enzyme inhibitors and atherosclerosis. J Physiol Pharmacol. 1994;45:13–25.[Medline] [Order article via Infotrieve]

18. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65–S72.

19. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model: a comparative study with captopril. Circulation. 1996;93:333–339.[Abstract/Free Full Text]

20. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]

21. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148.[Abstract/Free Full Text]

22. Chen XL, Tummala PE, Obrych MT, Medford RM. Oxidation-reduction and proteasome dependent activation of monocyte chemotactic protein-1 gene expression in human vascular cells. Circ Res. 1996;94:1276. Abstract.

23. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G: evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest. 1993;92:1564–1571.

24. Evans GA, Garcia GG, Erwin R, Howard OM, Farrar WL. Pervanadate stimulates the effects of interleukin-2 (IL-2) in human T cells and provides evidence for the activation of two distinct tyrosine kinase pathways by IL-1. J Biol Chem. 1994;269:23407–23412.[Abstract/Free Full Text]

25. Griendling KK, Taubman MB, Akers M, Mendlowitz M, Alexander RW. Characterization of phosphatidylinositol-specific phospholipase C from cultured vascular smooth muscle cells. J Biol Chem. 1991;266:15498–15504.[Abstract/Free Full Text]

26. Christensen PJ, Rolfe MW, Staniford TJ, Burdick MD, Toews GB, Strieter RM. Characterization of the production of monocyte chemoattractant protein-1 and IL-8 in an allogeneic immune response. J Immunol. 1993;151:1205–1213.[Abstract]

27. Chen XL, Tummala PE, Olliff L, Medford RM. E-selectin gene expression in vascular smooth muscle cells: evidence for a tissue-specific repressor protein. Circ Res. 1997;80:305–311.[Abstract/Free Full Text]

28. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. Science. 1995;270:296–299.[Abstract/Free Full Text]

29. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule-1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci. U S A. 1996;93:9114–9119.[Abstract/Free Full Text]

30. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 1995;76:980–986.[Abstract/Free Full Text]

31. Marrero MB, Paxton WG, Schieffer B, Ling BN, Bernstein KE. Angiotensin II signaling events mediated by tyrosine phosphorylation. Cell Signal. 1996;8:21–26.[Medline] [Order article via Infotrieve]

32. Suzuki A, Shinoda J, Oiso Y, Kozawa O. Tyrosine kinase is involved in angiotensin II-stimulated phospholipase D activation in aortic smooth muscle cells: function of Ca²⁺ influx. Atherosclerosis. 1996;121:119–127.[Medline] [Order article via Infotrieve]

33. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353–1362.

34. Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res. 1995;30:511–517. Review.[Medline] [Order article via Infotrieve]

35. Liao DF, Duff JL, Daum G, Pelech SL, Berk BC. Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells: role of Raf. Circ Res. 1996;79:1007–1014.[Abstract/Free Full Text]

36. Schorb W, Conrad KM, Singer HA, Dostal DE, Baker KM. Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:1151–1160.[Medline] [Order article via Infotrieve]

37. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem. 1995;270:13585–13588.[Abstract/Free Full Text]

38. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19:753–757.[Abstract/Free Full Text]

39. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived grown factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314–325.[Abstract/Free Full Text]

40. Satriano JA, Hora K, Shan Z, Stanley ER, Mori T, Schlondorff D. Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-, tumor necrosis factor-, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol. 1993;150:1971–1978.[Abstract]

41. Ueda A, Okuda K, Ohno S, Shirai A, Igarashi T, Matsunaga J, Kawamoto S, Ishigatsubo Y, Okubo T. NF-B and Sp1 regulate transcription of human monocyte chemoattractant protein-1 gene. J Immunol. 1994;153:2052–2063.[Abstract]

42. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-jun, c-fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129–22134.[Abstract/Free Full Text]

43. Rao GN, Lassegue B, Alexander RW, Griendling KK. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. Biochem J. 1994;299:197–201.

44. Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-fos, c-jun, and c-myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest. 1995;96:842–847.

45. Meyer M, Schreck R, Baeuerle PA. H₂O₂ and antioxidants have opposite effects on activation of NF-B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993;12:2005–2015.[Medline] [Order article via Infotrieve]

46. Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-B p65) transcriptional factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10:252–264.[Abstract/Free Full Text]

47. Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma: the role of constitutive NF-B activity. J Biol Chem. 1996;271:11317–11324.[Abstract/Free Full Text]

48. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthsarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide: potential role in atherogenesis. FEBS Lett. 1993;334:170–174.[Medline] [Order article via Infotrieve]

49. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. VCAM-1 gene transcription and expression is regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866–1874.

50. Weber C. Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. Immunol Res. 1996;15:30–37.[Medline] [Order article via Infotrieve]

51. Geng Y, Zhang B, Lotz M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J Immunol. 1993;151:6692–6700.[Abstract]

52. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74:589–607. Review.[Medline] [Order article via Infotrieve]

53. Hirano M, Osada S, Aoki T, Hosaka M, Inoue J, Ohno S. MEK kinase is involved in tumor necrosis factor -induced NF-B activation and degradation of IkB-a. J Biol Chem. 1996;271:13234–13238.[Abstract/Free Full Text]

54. Crews CM, Alessandrini A, Erickson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992;258:478–480.[Abstract/Free Full Text]

55. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270:14843–14846.[Free Full Text]

56. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinase in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;188:257–264.[Medline] [Order article via Infotrieve]

57. Duff JL, Minia BP, Berk BC. Mitogen-activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP-1) in vascular smooth muscle cells: effect of actinomycin D and antisense oligonucleotides. J Biol Chem. 1995;270:7161–7166.[Abstract/Free Full Text]

58. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GS, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677.[Abstract]

59. Capers QI, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997;30:1397–1402.[Abstract/Free Full Text]

60. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A. Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension. 1995;25:132–138.[Abstract/Free Full Text]

61. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension. 1991;18:132–141.[Abstract/Free Full Text]

62. Poon M, Hsu WC, Bogadanov VY, Taubman MB. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol. 1996;149:307–317.[Abstract]

63. Wenzel UO, Fouqueray B, Grandaliano G, Kim YS, Karamitsos C, Valente AJ, Abboud HE. Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ Res. 1995;77:503–509.[Abstract/Free Full Text]

64. Chen XL, Tummala PE, Olbrych M, Lausen JB, Harrison DG, Medford RM. Direct activation of aortic monocyte chemoattractant protein-1 gene expression in vivo and ex vivo by angiotensin II in experimental hypertension. Circulation. 1997;96(suppl I):I-285. Abstract.

This article has been cited by other articles:

				Y. Zhang, D. K. Deb, J. Kong, G. Ning, Y. Wang, G. Li, Y. Chen, Z. Zhang, S. Strugnell, Y. Sabbagh, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist Am J Physiol Renal Physiol, September 1, 2009; 297(3): F791 - F801. [Abstract] [Full Text] [PDF]

				A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF]

				X. C. Li and J. L. Zhuo Intracellular ANG II directly induces in vitro transcription of TGF-{beta}1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1034 - C1045. [Abstract] [Full Text] [PDF]

				W. Ni, Y. Zhan, H. He, E. Maynard, J. A. Balschi, and P. Oettgen Ets-1 Is a Critical Transcriptional Regulator of Reactive Oxygen Species and p47phox Gene Expression in Response to Angiotensin II Circ. Res., November 9, 2007; 101(10): 985 - 994. [Abstract] [Full Text] [PDF]

				S. Sahar, M. A. Reddy, C. Wong, L. Meng, M. Wang, and R. Natarajan Cooperation of SRC-1 and p300 With NF-{kappa}B and CREB in Angiotensin II-Induced IL-6 Expression in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1528 - 1534. [Abstract] [Full Text] [PDF]

				S. Koide, M. Okazaki, M. Tamura, K. Ozumi, H. Takatsu, F. Kamezaki, A. Tanimoto, H. Tasaki, Y. Sasaguri, Y. Nakashima, et al. PTEN reduces cuff-induced neointima formation and proinflammatory cytokines Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2824 - H2831. [Abstract] [Full Text] [PDF]

				G. Chipitsyna, Q. Gong, C. F. Gray, Y. Haroon, E. Kamer, and H. A. Arafat Induction of Monocyte Chemoattractant Protein-1 Expression by Angiotensin II in the Pancreatic Islets and {beta}-Cells Endocrinology, May 1, 2007; 148(5): 2198 - 2208. [Abstract] [Full Text] [PDF]

				J. Liu, T. Shimosawa, H. Matsui, F. Meng, S. C. Supowit, D. J. DiPette, K. Ando, and T. Fujita Adrenomedullin inhibits angiotensin II-induced oxidative stress via Csk-mediated inhibition of Src activity Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1714 - H1721. [Abstract] [Full Text] [PDF]

				A. Tone, K. Shikata, D. Ogawa, S. Sasaki, R. Nagase, M. Sasaki, K. Yozai, H. Kataoka Usui, S. Okada, J. Wada, et al. Changes of gene expression profiles in macrophages stimulated by angiotensin II -- Angiotensin II induces MCP-2 through AT1-receptor Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 45 - 50. [Abstract] [PDF]

				H.-Y. Yang, P.-F. Kao, T.-H. Chen, B. Tomlinson, W.-C. Ko, and P. Chan Effects of the Angiotensin II Type 1 Receptor Antagonist Valsartan on the Expression of Superoxide Dismutase in Hypertensive Patients J. Clin. Pharmacol., March 1, 2007; 47(3): 397 - 403. [Abstract] [Full Text] [PDF]

				J. Ruef, M. Browatzki, C. A. Pfeiffer, J. Schmidt, and R. Kranzhofer Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2 Vascular Medicine, February 1, 2007; 12(1): 23 - 27. [Abstract] [PDF]

				L. A. Cassis, D. L. Rateri, H. Lu, and A. Daugherty Bone Marrow Transplantation Reveals That Recipient AT1a Receptors Are Required to Initiate Angiotensin II-Induced Atherosclerosis and Aneurysms Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 380 - 386. [Abstract] [Full Text] [PDF]

				P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF]

				P. Libby and P. M. Ridker Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46. [Abstract] [Full Text] [PDF]

				K. Tsuchiya, T. Yoshimoto, Y. Hirono, T. Tateno, T. Sugiyama, and Y. Hirata Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-{kappa}B-dependent pathway in rat preadipocytes Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E771 - E778. [Abstract] [Full Text] [PDF]

				P. M Ridker, E. Danielson, N. Rifai, R. J. Glynn, and for the Val-MARC Investigators Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial Hypertension, July 1, 2006; 48(1): 73 - 79. [Abstract] [Full Text] [PDF]

				K. Takebayashi, S. Matsumoto, Y. Aso, and T. Inukai Aldosterone Blockade Attenuates Urinary Monocyte Chemoattractant Protein-1 and Oxidative Stress in Patients with Type 2 Diabetes Complicated by Diabetic Nephropathy J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2214 - 2217. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]

				M. Y. Liu, M. Eyries, C. Zhang, F. S. Santiago, and L. M. Khachigian Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1 Blood, March 15, 2006; 107(6): 2322 - 2329. [Abstract] [Full Text] [PDF]

				A. A. Elmarakby, J. E. Quigley, D. M. Pollock, and J. D. Imig Tumor Necrosis Factor {alpha} Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension Hypertension, March 1, 2006; 47(3): 557 - 562. [Abstract] [Full Text] [PDF]

				D M Shavelle Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart, October 1, 2005; 91(10): 1257 - 1259. [Abstract] [Full Text] [PDF]

				T. Umekawa, K. Byer, H. Uemura, and S. R. Khan Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells Nephrol. Dial. Transplant., May 1, 2005; 20(5): 870 - 878. [Abstract] [Full Text] [PDF]

				M. Jaramillo, M. Godbout, and M. Olivier Hemozoin Induces Macrophage Chemokine Expression through Oxidative Stress-Dependent and -Independent Mechanisms J. Immunol., January 1, 2005; 174(1): 475 - 484. [Abstract] [Full Text] [PDF]

				M. Jaramillo, M. Godbout, P. H. Naccache, and M. Olivier Signaling Events Involved in Macrophage Chemokine Expression in Response to Monosodium Urate Crystals J. Biol. Chem., December 10, 2004; 279(50): 52797 - 52805. [Abstract] [Full Text] [PDF]

				S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]

				M. T. Johnstone, A. S. Perez, I. Nasser, R. Stewart, A. Vaidya, F. Al Ammary, B. Schmidt, G. Horowitz, J. Dolgoff, J. Hamilton, et al. Angiotensin Receptor Blockade With Candesartan Attenuates Atherosclerosis, Plaque Disruption, and Macrophage Accumulation Within the Plaque in a Rabbit Model Circulation, October 5, 2004; 110(14): 2060 - 2065. [Abstract] [Full Text] [PDF]

				L. Mazzolai, M. A. Duchosal, M. Korber, K. Bouzourene, J. F. Aubert, H. Hao, V. Vallet, H. R. Brunner, J. Nussberger, G. Gabbiani, et al. Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE-/- Mice Hypertension, September 1, 2004; 44(3): 277 - 282. [Abstract] [Full Text] [PDF]

				G. Spinetti, M. Wang, R. Monticone, J. Zhang, D. Zhao, and E. G. Lakatta Rat Aortic MCP-1 and Its Receptor CCR2 Increase With Age and Alter Vascular Smooth Muscle Cell Function Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1397 - 1402. [Abstract] [Full Text] [PDF]

				T. Yoshimoto, N. Fukai, R. Sato, T. Sugiyama, N. Ozawa, M. Shichiri, and Y. Hirata Antioxidant Effect of Adrenomedullin on Angiotensin II-Induced Reactive Oxygen Species Generation in Vascular Smooth Muscle Cells Endocrinology, July 1, 2004; 145(7): 3331 - 3337. [Abstract] [Full Text] [PDF]

				K. Tsunemi, S. Takai, M. Nishimoto, D. Jin, M. Sakaguchi, M. Muramatsu, A. Yuda, S. Sasaki, and M. Miyazaki A Specific Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppresses Development of Abdominal Aortic Aneurysm in Hamsters J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 879 - 883. [Abstract] [Full Text] [PDF]

				M. Ishibashi, K.-i. Hiasa, Q. Zhao, S. Inoue, K. Ohtani, S. Kitamoto, M. Tsuchihashi, T. Sugaya, I. F. Charo, S. Kura, et al. Critical Role of Monocyte Chemoattractant Protein-1 Receptor CCR2 on Monocytes in Hypertension-Induced Vascular Inflammation and Remodeling Circ. Res., May 14, 2004; 94(9): 1203 - 1210. [Abstract] [Full Text] [PDF]

				B. Jiang, S. Xu, X. Hou, D. R. Pimentel, and R. A. Cohen Angiotensin II Differentially Regulates Interleukin-1-{beta}-inducible NO Synthase (iNOS) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression: ROLE OF p38 MAPK J. Biol. Chem., May 7, 2004; 279(19): 20363 - 20368. [Abstract] [Full Text] [PDF]

				S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, and T. Iwasaka Effects of Losartan and Simvastatin on Monocyte-Derived Microparticles in Hypertensive Patients With and Without Type 2 Diabetes Mellitus Clinical and Applied Thrombosis/Hemostasis, April 1, 2004; 10(2): 133 - 141. [Abstract] [PDF]

				R. Candido, T. J. Allen, M. Lassila, Z. Cao, V. Thallas, M. E. Cooper, and K. A. Jandeleit-Dahm Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis Circulation, March 30, 2004; 109(12): 1536 - 1542. [Abstract] [Full Text] [PDF]

				L. Wu, M. Iwai, Z. Li, T. Shiuchi, L.-J. Min, T.-X. Cui, J.-M. Li, M. Okumura, C. Nahmias, and M. Horiuchi Regulation of Inhibitory Protein-{kappa}B and Monocyte Chemoattractant Protein-1 by Angiotensin II Type 2 Receptor-Activated Src Homology Protein Tyrosine Phosphatase-1 in Fetal Vascular Smooth Muscle Cells Mol. Endocrinol., March 1, 2004; 18(3): 666 - 678. [Abstract] [Full Text] [PDF]

				W. Ni, S. Kitamoto, M. Ishibashi, M. Usui, S. Inoue, K.-i. Hiasa, Q. Zhao, K.-i. Nishida, A. Takeshita, and K. Egashira Monocyte Chemoattractant Protein-1 Is an Essential Inflammatory Mediator in Angiotensin II-Induced Progression of Established Atherosclerosis in Hypercholesterolemic Mice Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 534 - 539. [Abstract] [Full Text]

				T. Omura, M. Yoshiyama, S. Kim, R. Matsumoto, Y. Nakamura, Y. Izumi, H. Ichijo, T. Sudo, K. Akioka, H. Iwao, et al. Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 270 - 275. [Abstract] [Full Text]

				Y. Taniyama and K. K. Griendling Reactive Oxygen Species in the Vasculature: Molecular and Cellular Mechanisms Hypertension, December 1, 2003; 42(6): 1075 - 1081. [Abstract] [Full Text] [PDF]

				S. Oparil, M. A. Zaman, and D. A. Calhoun Pathogenesis of Hypertension Ann Intern Med, November 4, 2003; 139(9): 761 - 776. [Full Text] [PDF]

				M. Higashi, H. Shimokawa, T. Hattori, J. Hiroki, Y. Mukai, K. Morikawa, T. Ichiki, S. Takahashi, and A. Takeshita Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II-Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System Circ. Res., October 17, 2003; 93(8): 767 - 775. [Abstract] [Full Text] [PDF]

				B. Amann, R. Tinzmann, and B. Angelkort ACE Inhibitors Improve Diabetic Nephropathy Through Suppression of Renal MCP-1 Diabetes Care, August 1, 2003; 26(8): 2421 - 2425. [Abstract] [Full Text] [PDF]

				D. G Harrison, Hua Cai, U. Landmesser, and K. K Griendling The Pickering Lecture British Hypertension Society, 10th September 2002: Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 51 - 61. [Abstract] [PDF]

				J. M. Proudfoot, K. D. Croft, I. B. Puddey, and L. J. Beilin Angiotensin II Type 1 Receptor Antagonists Inhibit Basal As Well As Low-Density Lipoprotein and Platelet-Activating Factor-Stimulated Human Monocyte Chemoattractant Protein-1 J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 846 - 853. [Abstract] [Full Text] [PDF]

				X.-L. Chen, Q. Zhang, R. Zhao, X. Ding, P. E. Tummala, and R. M. Medford Rac1 and Superoxide Are Required for the Expression of Cell Adhesion Molecules Induced by Tumor Necrosis Factor-alpha in Endothelial Cells J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 573 - 580. [Abstract] [Full Text] [PDF]

				G. G. Deng, B. Martin-McNulty, D. A. Sukovich, A. Freay, M. Halks-Miller, T. Thinnes, D. J. Loskutoff, P. Carmeliet, W. P. Dole, and Y.-X. Wang Urokinase-Type Plasminogen Activator Plays a Critical Role in Angiotensin II-Induced Abdominal Aortic Aneurysm Circ. Res., March 21, 2003; 92(5): 510 - 517. [Abstract] [Full Text] [PDF]

				G. Castoldi, C. R. T. di Gioia, F. Pieruzzi, C. D'Orlando, W. M. M. van de Greef, G. Busca, G. Sperti, and A. Stella ANG II increases TIMP-1 expression in rat aortic smooth muscle cells in vivo Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H635 - H643. [Abstract] [Full Text] [PDF]

				A. H. Campos, Y. Zhao, M. J. Pollman, and G. H. Gibbons DNA Microarray Profiling to Identify Angiotensin-Responsive Genes in Vascular Smooth Muscle Cells: Potential Mediators of Vascular Disease Circ. Res., January 10, 2003; 92(1): 111 - 118. [Abstract] [Full Text] [PDF]

				X.-L. Chen, S. E. Varner, A. S. Rao, J. Y. Grey, S. Thomas, C. K. Cook, M. A. Wasserman, R. M. Medford, A. K. Jaiswal, and C. Kunsch Laminar Flow Induction of Antioxidant Response Element-mediated Genes in Endothelial Cells. A NOVEL ANTI-INFLAMMATORY MECHANISM J. Biol. Chem., January 3, 2003; 278(2): 703 - 711. [Abstract] [Full Text] [PDF]

				U. Landmesser and H. Drexler Oxidative stress, the renin-angiotensin system, and atherosclerosis Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A3 - A7. [Abstract] [PDF]

				R. De Caterina and C. Manes Inflammation in early atherogenesis: impact of ACE inhibition Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A15 - A24. [Abstract] [PDF]

				M. Jaramillo and M. Olivier Hydrogen Peroxide Induces Murine Macrophage Chemokine Gene Transcription Via Extracellular Signal-Regulated Kinase- and Cyclic Adenosine 5'-Monophosphate (cAMP)-Dependent Pathways: Involvement of NF-{kappa}B, Activator Protein 1, and cAMP Response Element Binding Protein J. Immunol., December 15, 2002; 169(12): 7026 - 7038. [Abstract] [Full Text] [PDF]

				K. D. O'Brien, D. M. Shavelle, M. T. Caulfield, T. O. McDonald, K. Olin-Lewis, C. M. Otto, and J. L. Probstfield Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma Circulation, October 22, 2002; 106(17): 2224 - 2230. [Abstract] [Full Text] [PDF]

				J. X. Rong, J. W. Berman, M. B. Taubman, and E. A. Fisher Lysophosphatidylcholine Stimulates Monocyte Chemoattractant Protein-1 Gene Expression in Rat Aortic Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1617 - 1623. [Abstract] [Full Text] [PDF]

				O. Sekine, Y. Nishio, K. Egawa, T. Nakamura, H. Maegawa, and A. Kashiwagi Insulin Activates CCAAT/Enhancer Binding Proteins and Proinflammatory Gene Expression through the Phosphatidylinositol 3-Kinase Pathway in Vascular Smooth Muscle Cells J. Biol. Chem., September 20, 2002; 277(39): 36631 - 36639. [Abstract] [Full Text] [PDF]

				M. W Manning, L. A Cassis, J. Huang, S. J Szilvassy, and A. Daugherty Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease Vascular Medicine, February 1, 2002; 7(1): 45 - 54. [Abstract] [PDF]

				C. Kataoka, K. Egashira, S. Inoue, M. Takemoto, W. Ni, M. Koyanagi, S. Kitamoto, M. Usui, K. Kaibuchi, H. Shimokawa, et al. Important Role of Rho-kinase in the Pathogenesis of Cardiovascular Inflammation and Remodeling Induced by Long-Term Blockade of Nitric Oxide Synthesis in Rats Hypertension, February 1, 2002; 39(2): 245 - 250. [Abstract] [Full Text] [PDF]

				D. M. Attia, A. M. G. Verhagen, E. S. G. Stroes, E. E. van Faassen, H.-J. Grone, S. J. De Kimpe, H. A. Koomans, B. Braam, and J. A. Joles Vitamin E Alleviates Renal Injury, but Not Hypertension, during Chronic Nitric Oxide Synthase Inhibition in Rats J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2585 - 2593. [Abstract] [Full Text] [PDF]

				T. Suganami, M. Mukoyama, A. Sugawara, K. Mori, T. Nagae, M. Kasahara, K. Yahata, H. Makino, Y. Fujinaga, Y. Ogawa, et al. Overexpression of Brain Natriuretic Peptide in Mice Ameliorates Immune-Mediated Renal Injury J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2652 - 2663. [Abstract] [Full Text] [PDF]

				M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, Y. Suzuki, S. Mezzano, J.J. Plaza, and J. Egido Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field Hypertension, December 1, 2001; 38(6): 1382 - 1387. [Abstract] [Full Text] [PDF]

				L. Wu, M. Iwai, H. Nakagami, Z. Li, R. Chen, J. Suzuki, M. Akishita, M. de Gasparo, and M. Horiuchi Roles of Angiotensin II Type 2 Receptor Stimulation Associated With Selective Angiotensin II Type 1 Receptor Blockade With Valsartan in the Improvement of Inflammation-Induced Vascular Injury Circulation, November 27, 2001; 104(22): 2716 - 2721. [Abstract] [Full Text] [PDF]

				Y.-X. Wang, B. Martin-McNulty, A. D. Freay, D. A. Sukovich, M. Halks-Miller, W.-W. Li, R. Vergona, M. E. Sullivan, J. Morser, W. P. Dole, et al. Angiotensin II Increases Urokinase-Type Plasminogen Activator Expression and Induces Aneurysm in the Abdominal Aorta of Apolipoprotein E-Deficient Mice Am. J. Pathol., October 1, 2001; 159(4): 1455 - 1464. [Abstract] [Full Text]

				K. F. Hilgers, A. Hartner, M. Porst, R. Veelken, and J. F.E. Mann Angiotensin II Type 1 Receptor Blockade Prevents Lethal Malignant Hypertension: Relation to Kidney Inflammation Circulation, September 18, 2001; 104(12): 1436 - 1440. [Abstract] [Full Text] [PDF]

				P. Libby Current Concepts of the Pathogenesis of the Acute Coronary Syndromes Circulation, July 17, 2001; 104(3): 365 - 372. [Full Text] [PDF]

				Y. Funakoshi, T. Ichiki, H. Shimokawa, K. Egashira, K. Takeda, K. Kaibuchi, M. Takeya, T. Yoshimura, and A. Takeshita Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells Hypertension, July 1, 2001; 38(1): 100 - 104. [Abstract] [Full Text] [PDF]

				S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]

				V. Papademetriou, P. Mammillot, R. Redman, A. Notargiacomo, P. Narayan, and R. Lakshman Prevention of atherosclerosis by specific AT1-receptor blockade with candesartan cilexetil Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S77 - S80. [Abstract] [PDF]

				U. Kintscher, S. Wakino, S. Kim, E. Fleck, W. A. Hsueh, and R. E. Law Angiotensin II Induces Migration and Pyk2/Paxillin Phosphorylation of Human Monocytes Hypertension, February 1, 2001; 37(2): 587 - 593. [Abstract] [Full Text] [PDF]

				D. Weiss, J. J. Kools, and W. R. Taylor Angiotensin II-Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice Circulation, January 23, 2001; 103(3): 448 - 454. [Abstract] [Full Text] [PDF]

				R. M. Touyz and E. L. Schiffrin Signal Transduction Mechanisms Mediating the Physiological and Pathophysiological Actions of Angiotensin II in Vascular Smooth Muscle Cells Pharmacol. Rev., December 1, 2000; 52(4): 639 - 672. [Abstract] [Full Text] [PDF]

				K. K. Griendling, D. Sorescu, B. Lassegue, and M. Ushio-Fukai Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2175 - 2183. [Abstract] [Full Text] [PDF]

				T. M. Behr, X. Wang, N. Aiyar, R. W. Coatney, X. Li, P. Koster, C. E. Angermann, E. Ohlstein, G. Z. Feuerstein, and J. Winaver Monocyte Chemoattractant Protein-1 is Upregulated in Rats With Volume-Overload Congestive Heart Failure Circulation, September 12, 2000; 102(11): 1315 - 1322. [Abstract] [Full Text] [PDF]

				D. Li and J. L. Mehta Antisense to LOX-1 Inhibits Oxidized LDL-Mediated Upregulation of Monocyte Chemoattractant Protein-1 and Monocyte Adhesion to Human Coronary Artery Endothelial Cells Circulation, June 27, 2000; 101(25): 2889 - 2895. [Abstract] [Full Text] [PDF]

				M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, S. Konig, B. Wittig, and J. Egido Angiotensin II Activates Nuclear Transcription Factor {kappa}B Through AT1 and AT2 in Vascular Smooth Muscle Cells : Molecular Mechanisms Circ. Res., June 23, 2000; 86(12): 1266 - 1272. [Abstract] [Full Text] [PDF]

				D. E. Vaughan AT1 Receptor Blockade and Atherosclerosis : Hopeful Insights Into Vascular Protection Circulation, April 4, 2000; 101(13): 1496 - 1497. [Full Text] [PDF]

				K. K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H Oxidase : Role in Cardiovascular Biology and Disease Circ. Res., March 17, 2000; 86(5): 494 - 501. [Abstract] [Full Text] [PDF]

				W. B Strawn, R. H Dean, and C. M Ferrario Novel mechanisms linking angiotensin II and early atherogenesis Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 11 - 17. [PDF]

				S. Kim and H. Iwao Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases Pharmacol. Rev., March 1, 2000; 52(1): 11 - 34. [Abstract] [Full Text] [PDF]

				G. W. De Keulenaer, M. Ushio-Fukai, Q. Yin, A. B. Chung, P. R. Lyons, N. Ishizaka, K. Rengarajan, W. R. Taylor, R. W. Alexander, and K. K. Griendling Convergence of Redox-Sensitive and Mitogen-Activated Protein Kinase Signaling Pathways in Tumor Necrosis Factor-{alpha}-Mediated Monocyte Chemoattractant Protein-1 Induction in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 385 - 391. [Abstract] [Full Text] [PDF]

				C. Kunsch and R. M. Medford Oxidative Stress as a Regulator of Gene Expression in the Vasculature Circ. Res., October 15, 1999; 85(8): 753 - 766. [Abstract] [Full Text] [PDF]

				Y.-M. Go, R. P. Patel, M. C. Maland, H. Park, J. S. Beckman, V. M. Darley-Usmar, and H. Jo Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH2-terminal kinase Am J Physiol Heart Circ Physiol, October 1, 1999; 277(4): H1647 - H1653. [Abstract] [Full Text] [PDF]

				T. Kita LOX-1, a Possible Clue to the Missing Link Between Hypertension and Atherogenesis Circ. Res., May 14, 1999; 84(9): 1113 - 1115. [Full Text] [PDF]

				H. P. Brunner-La Rocca, G. Vaddadi, and M. D. Esler Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1163 - 1173. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, X.-L. Articles by Medford, R. M. Search for Related Content PubMed PubMed Citation Articles by Chen, X.-L. Articles by Medford, R. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB HYDROGEN PEROXIDE NITRIC OXIDE